The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Antibody drug conjugates (ADC) cancer therapy are a key innovation area in immuno-oncology
Antibody-drug conjugates or ADCs are a new class of biopharmaceutical drugs composed of an antibody that is linked via a chemical linker to a cytotoxic payload. The monoclonal antibody binds to receptors found on cancer cells and the linked drug enters these cells, killing them without harming healthy cells. Enhertu, Kadcyla, Blenrep, and Adcetris are some of the examples of approved ADCs.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 160+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of ADC cancer therapy.
Key players in antibody drug conjugates (ADC) cancer therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to antibody drug conjugates (ADC) cancer therapy
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche is one of the leading patent filers for ADC cancer therapeutics. The approved ADCs under the company are Kadcyla, RoPolivy, 212 Pb-TCMC-Trastuzumab, and 212 Pb-PRIT. The company’s robust R&D capabilities enable it to address unmet medical needs for oncology, haematology, immunology, infectious diseases, ophthalmology, and neurological disorders. Gilead Sciences is the second leading patent filer for ADCs as cancer therapeutics. Gilead Sciences’ sacituzumab govitecan got market authorization for Metastatic Transitional (Urothelial) Tract Cancer and Triple-Negative Breast Cancer (TNBC). Labetuzumab govitecan and IMMU-140 are under development for further oncology indications
In terms of application diversity, Immatics is the top company followed by Astellas Pharma and C. H. Boehringer Sohn. By means of geographic reach, EnGeneIC holds the top position. Fredax and Oxford BioTherapeutics are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.